Bicycle Therapeutics plc (BCYC): Price and Financial Metrics


Bicycle Therapeutics plc (BCYC)

Today's Latest Price: $20.58 USD

0.09 (-0.44%)

Updated Dec 3 12:57pm

Add BCYC to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

BCYC Stock Summary

  • BICYCLE THERAPEUTICS plc's stock had its IPO on May 23, 2019, making it an older stock than just 2.42% of US equities in our set.
  • With a price/sales ratio of 37.25, BICYCLE THERAPEUTICS plc has a higher such ratio than 94.49% of stocks in our set.
  • With a year-over-year growth in debt of 964.41%, BICYCLE THERAPEUTICS plc's debt growth rate surpasses 97.99% of about US stocks.
  • Stocks that are quantitatively similar to BCYC, based on their financial statements, market capitalization, and price volatility, are CDXS, DSPG, FPRX, FREQ, and NVCN.
  • Visit BCYC's SEC page to see the company's official filings. To visit the company's web site, go to www.bicycletherapeutics.com.

BCYC Stock Price Chart Interactive Chart >

Price chart for BCYC

BCYC Price/Volume Stats

Current price $20.58 52-week high $22.71
Prev. close $20.67 52-week low $7.50
Day low $20.25 Volume 22,487
Day high $21.68 Avg. volume 47,179
50-day MA $19.36 Dividend yield N/A
200-day MA $16.80 Market Cap 364.18M

Bicycle Therapeutics plc (BCYC) Company Bio


Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.


BCYC Latest News Stream


Event/Time News Detail
Loading, please wait...

BCYC Latest Social Stream


Loading social stream, please wait...

View Full BCYC Social Stream

Latest BCYC News From Around the Web

Below are the latest news stories about BICYCLE THERAPEUTICS plc that investors may wish to consider to help them evaluate BCYC as an investment opportunity.

Bicycle Therapeutics closes ATM offering; debt financing with Hercules Capital

Bicycle Therapeutics (BCYC) completed its at-the-market offering program initiated during Q3 generating gross proceeds of $50M.Also, it closed a financing with Hercules Capital (HTGC) for a term loan of up to $40M in two tranches; an initial tranche of $30M will be fully available at the loan closing, with a minimum draw...

Seeking Alpha | October 1, 2020

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...

Benzinga | September 16, 2020

VBL Therapeutics's Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma

VBL Therapeutics reports progress for metastatic colorectal cancer trial VBL Therapeutics (VBLT) announced the enrollment of the first two patients for its Phase 2 clinical trial of VB-111. The trial is designed to evaluate the potential of VB-111 used in combination with nivolumab for treating metastatic colorectal cancer. The company...

Avisol Capital Partners on Seeking Alpha | September 15, 2020

The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Altimmune Inc (NASDAQ: ALT ) (priced its $115 million worth of common stock and pre-funded warrant offering) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Imv Inc (NASDAQ: IMV ) (provided an update on its coronavirus vaccine program) INmune Bio Inc (NASDAQ: INMB )( announced positive interim Phase 1b data for its Alzheimer's drug) OncoSec Medical Inc (NASDAQ: ONCS ) Qiagen NV (NYSE: QGEN ) Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL ) (announced initiation of clinical study of its fostamatinib for treating COVID-19 pneumonia) TIZIANA LF SCIE/S ADR (NASDAQ: TLSA ) Vaxart Inc (NASDAQ:...

Benzinga | July 15, 2020

Bicycle Therapeutics (BCYC) Catches Eye: Stock Jumps 8.9%

Bicycle Therapeutics (BCYC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Yahoo | June 24, 2020

Read More 'BCYC' Stories Here

BCYC Price Returns

1-mo 9.35%
3-mo 19.17%
6-mo 18.28%
1-year 166.93%
3-year N/A
5-year N/A
YTD 118.24%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7694 seconds.